Serotonin-2C receptors in the basolateral nucleus of the amygdala mediate the anxiogenic effect of acute imipramine and fluoxetine administration

International Journal of Neuropsychopharmacology

Volumn 15, Issue 3, 2012, Pages 389-400

  Vicente, Maria Adrielle ^a   Zangrossi, Helio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antidepressant; anxiety; basolateral amygdala; serotonin

Indexed keywords

6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; FLUOXETINE; IMIPRAMINE; SEROTONIN; SEROTONIN 2C RECEPTOR; 6-CHLORO-5-METHYL-1-((2-(2-METHYLPYRID-3-YLOXY)PYRID-5-YL)CARBAMOYL)INDOLINE; AMINOPYRIDINE DERIVATIVE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; INDOLE DERIVATIVE; PYRAZINE DERIVATIVE; SEROTONIN 2 AGONIST; SEROTONIN 2 ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT;

ACUTE DRUG ADMINISTRATION; AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFLICT; CONTROLLED STUDY; DRUG MECHANISM; ESCAPE BEHAVIOR; GENERALIZED ANXIETY DISORDER; MALE; MAZE TEST; MICROINJECTION; NONHUMAN; PANIC; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; ANIMAL; ANXIETY DISORDERS; AVOIDANCE BEHAVIOR; BASOLATERAL AMYGDALA; DRUG EFFECTS; EXPLORATORY BEHAVIOR; METABOLISM; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

AMINOPYRIDINES; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; AVOIDANCE LEARNING; BASOLATERAL NUCLEAR COMPLEX; EXPLORATORY BEHAVIOR; FLUOXETINE; IMIPRAMINE; INDOLES; MALE; MAZE LEARNING; NEUROPSYCHOLOGICAL TESTS; PYRAZINES; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84858773310     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000873     Document Type: Article

References (67)

1. Aloyo VJ, Berg KA, Spampinato U, Clarke WP, et al. (2009). Current status ofinverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. Pharmacology and Therapeutics 121, 160-173.
2. Alves SH, Pinheiro G, Motta V, Landeira-Fernandez J, et al. (2004). Anxiogenic effects in the rat elevated plus-maze of 5-HT(2C) agonists into ventral but not dorsal hippocampus. Behavioural Pharmacology 15, 37-43. (Pubitemid 38241512)
3. Bagdy G, Graf M, Anheuer ZE, Modos EA, et al. (2001). Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. International Journal of Neuropsychopharmacology 4, 399-408. (Pubitemid 33151684)
4. Bakker A, van Balkom AJ, Stein DJ (2005). Evidence-based pharmacotherapy of panic disorder. International Journal of Neuropsychopharmacology 8, 473-482. (Pubitemid 41002501)
5. Berg KA, Clarke WP, Cunningham KA, Spampinato U (2008). Fine-tuning serotonin2c receptor function in the brain : molecular and functional implications. Neuropharmacology 55, 969-976.
6. Blanchard DC, Griebel G, Blanchard RJ (2001). Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neuroscience and Biobehavioral Reviews 25, 205-218. (Pubitemid 32506874)
7. Blanchard DC, Griebel G, Blanchard RJ (2003). The Mouse Defense Test Battery : pharmacological and behavioral assays for anxiety and panic. European Journal of Pharmacology 463, 97-116. (Pubitemid 36205074)
8. Bockaert J, Claeysen S, Dumuis A, Marin P (2010). Classification and signaling characteristics of 5-HT receptors. In : Muller CP, Jacobs BL (Eds), Handbook of the Behavioral Neurobiology of Serotonin (pp. 102-122). San Diego: Elsevier.
9. Bosker FJ, Cremers TI, Jongsma ME, Westerink BH, et al. (2001). Acute and chronic effects of citalopram on postsynaptic 5-hydroxytryptamine(1A) receptor-mediated feedback: A microdialysis study in the amygdala. Journal of Neurochemistry 6, 1645-1653. (Pubitemid 32221104)
10. Bressa GM, Marini S, Gregori S (1987). Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam. International Journal of Clinical Pharmacology Research 2, 111-119. (Pubitemid 17058312)
11. Broocks A, Briggs NC, Pigott TA, Hill JL, et al. (1997). Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment. Psychopharmacology (Berlin) 130, 91-103. (Pubitemid 27132753)
12. Burghardt NS, Bush DE, McEwen BS, LeDoux JE (2007). Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT(2C) receptor antagonist. Biological Psychiatry 62, 1111-1118. (Pubitemid 350029715)
13. Campbell BM, Merchant KM (2003). Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Research 993, 1-9. (Pubitemid 37464577)
14. Ceulemans DL, Hoppenbrouwers ML, Gelders YG, Reyntjens AJ (1985). The influence of ritanserin, a serotonin antagonist, in anxiety disorders : A double-blind placebo-controlled study vs. lorazepam. Pharmacopsychiatry 18, 303-305. (Pubitemid 16255815)
15. Christianson JP, Ragole T, Amat J, Greenwood BN, et al. (2010). 5-hydroxytryptamine 2C receptors in the basolateral amygdala are involved in the expression of anxiety after uncontrollable traumatic stress. Biological Psychiatry 67, 339-345.
16. Clemett DA, Punhani T, Duxon MS, Blackburn TP, et al. (2000). Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 39, 123-132.
17. de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, et al. (2010). Agomelatine, the first melatonergic antidepressant : discovery, characterization and development. Nature Reviews Drug Discovery 8, 628-642.
18. de Mello Cruz AP, Pinheiro G, Alves SH, Ferreira G, et al. (2005). Behavioral effects of systemically administered MK-212 are prevented by ritanserin microinfusion into the basolateral amygdala of rats exposed to the elevated plus-maze. Psychopharmacology (Berlin) 182, 345-354. (Pubitemid 41464646)
19. Dupuy JM, Ostacher MJ, Huffman J, Perlis RH, et al. (2011). A critical review of pharmacotherapy for major depressive disorder. International Journal of Neuropsychopharmacology 24, 1-15.
20. Giorgetti M, Tecott LH (2004). Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. European Journal of Pharmacology 488, 1-9. (Pubitemid 38388517)
21. Gobert A, Brocco M, Dekeyne A, Di Cara B, et al. (2009). Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions : A neurochemical, electrophysiological, and behavioral characterization. Neuropsychopharmacology 34, 1039-1056.
22. Graeff FG, Zangrossi H (2002). Animal models of anxiety disorders. In : D'Haenen H, den Boer JA, Westenberg H, Willner P (Eds), Textbook of Biological Psychiatry (pp. 879-893). London: Wiley and Sons.
23. Gray JA, McNaughton N (2000). Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. Journal Affect Disorders 61, 161-176. (Pubitemid 32119264)
24. Greenwood BN, Strong PV, Brooks L, Fleshner M (2008). Anxiety-like behaviors produced by acute fluoxetine administration in male Fischer 344 rats are prevented by prior exercise. Psychopharmacology (Berlin) 199, 209-222.
25. Harada K, Yamaji T, Matsuoka N (2008). Activation of the serotonin 5-HT2C receptor is involved in the enhanced anxiety in rats after single-prolonged stress. Pharmacology, Biochemistry, and Behavior 89, 11-16.
26. Heisler LK, Zhou L, Bajwa P, Hsu J, et al. (2007). Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. Genes Brain and Behavior 6, 491-496. (Pubitemid 47024962)
27. Hoyer D, Hannon JP, Martin GR (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacology, Biochemistry, and Behavior 71, 533-554. (Pubitemid 34219205)
28. Jan RK, Lin JC, Lee H, Sheridan JL, et al. (2010). Determining the subjective effects of TFMPP in human males. Psychopharmacology (Berlin) 211, 347-353.
29. Kennett GA, Whitton P, Shah K, Curzon G (1989). Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. European Journal of Pharmacology 164, 445-454. (Pubitemid 19146953)
30. Kennett GA, Wood MD, Bright F, Trail B, et al. (1997). SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36, 609-620. (Pubitemid 27272106)
31. Kimura A, Stevenson PL, Carter RN, Maccoll G, et al. (2009). Overexpression of 5-HT2C receptors in forebrain leads to elevated anxiety and hypoactivity. European Journal of Neuroscience 30, 299-306.
32. Knight AR, Misra A, Quirk K, Benwell K, et al. (2004). Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn-Schmiedeberg's Archives of Pharmacology 370, 114-123. (Pubitemid 39222863)
33. Landolt HP, Wehrle R (2009). Antagonism of serotonergic 5-HT2A/2C receptors : mutual improvement of sleep, cognition and mood? European Journal of Neuroscience 29, 1795-1809.
34. Martin JR, Ballard TM, Higgins GA (2002). Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacology, Biochemistry, and Behavior 71, 615-625. (Pubitemid 34219212)
35. Martinez RC, Ribeiro de Oliveira A, Brandão ML (2007). Serotonergic mechanisms in the basolateral amygdala differentially regulate the conditioned and unconditioned fear organized in the periaqueductal gray. European Neuropsychopharmacology 17, 717-724. (Pubitemid 47419292)
36. McNaughton N, Corr PJ (2004). A two-dimensional neuropsychology of defense : fear/anxiety and defensive distance. Neuroscience and Biobehavioral Reviews 28, 285-305. (Pubitemid 38844377)
37. McNaughton N, Gray JA (2000). Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. Journal of Affective Disorders 61, 161-176. (Pubitemid 32119264)
38. McNaughton N, Zangrossi HJ (2008). Animal models of anxiety, fear and defense: theoretical to the modeling of anxiety in animals. In : Blanchard R, Blanchard D, Griebel G, Nutt D (Eds), Handbook of Anxiety and Fear (pp. 11-27). Amsterdam: Elsevier.
39. Mengod G, Cortés R, Vilaró MT, Hoyer D (2010). Distribution of 5-HT receptors in the central nervous system. In : Muller CP, Jacobs BL (Eds), Handbook of the Behavioral Neurobiology of Serotonin (pp. 123-139). San Diego: Elsevier.
40. Millan MJ (2003). The neurobiology and control of anxious states. Progress in Neurobiology 70, 83-244. (Pubitemid 37309295)
41. Millan MJ (2005). Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states : focus on novel therapeutic strategies. Therapie 60, 441-460.
42. Millan MJ, Brocco M (2003). The Vogel conflict test : procedural aspects, gamma-aminobutyric acid, glutamate and monoamines. European Journal of Pharmacology 463, 67-96. (Pubitemid 36205073)
43. Millan MJ, Brocco M, Gobert A, Dekeyne A (2005). Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties : role of 5-HT2C receptor blockade. Psychopharmacology (Berlin) 177, 448-458.
44. Navailles S, Moison D, Ryczko D, Spampinato U (2006). Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptors. Journal of Neurochemistry 99, 1311-1319. (Pubitemid 44655294)
45. Ni YG, Miledi R (1997). Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proceedings of the National Academy of Sciences USA 94, 2036-2040.
46. Overstreet DH, Knapp DJ, Angel RA, Navarro M, et al. (2006). Reduction in repeated ethanol-withdrawal-induced anxiety-like behavior by site-selective injections of 5-HT1A and 5-HT2C ligands. Psychopharmacology (Berlin) 187, 1-12. (Pubitemid 43876910)
47. Overstreet DH, Knapp DJ, Moy SS, Breese GR (2003). A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats. Psychopharmacology (Berlin) 167, 344-352. (Pubitemid 36754235)
48. Pälvimäki EP, Roth BL, Majasuo H, Laakso A, et al. (1996). Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berlin) 126, 234-240. (Pubitemid 26252760)
49. Paxinos G, Watson C (2007). The Rat Brain in Stereotaxic Coordinates, 6th edn. San Diego: Academic Press.
50. Pazos A, Hoyer D, Palacios JM (1984). The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. European Journal of Pharmacology 106, 539-546. (Pubitemid 15194103)
51. Pelosi GG, Resstel LL, Soares VP, Zangrossi H, et al. (2009). Anxiolytic-like effect of noradrenaline microinjection into the dorsal periaqueductal gray of rats. Behavioural Pharmacology 20, 252-259.
52. Pesold C, Treit D (1995). The central and basolateral amygdala differentially mediate the anxiolytic effects of benzodiazepines. Brain Research 671, 213-221.
53. Pinheiro SH, Zangrossi H, Del-Ben CM, Graeff FG (2007). Elevated mazes as animal models of anxiety : effects of serotonergic agents. Anais da Academia Brasileira de Ciências 79, 71-85. (Pubitemid 46516260)
54. Poltronieri SC, Zangrossi H, de Barros Viana M (2003). Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze. Behavioural Brain Research 147, 185-192. (Pubitemid 37491426)
55. Pompeiano M, Palacios JM, Mengod G (1994). Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Behavioural Brain Research 23, 163-178.
56. Ravindran LN, Stein MB (2010). The pharmacologic treatment of anxiety disorders : A review of progress. Journal of Clinical Psychiatry 7, 839-854.
57. Rosen JB (2004). The neurobiology of conditioned and unconditioned fear : A neurobehavioral system analysis of the amygdala. Behavioral and Cognitive Neuroscience Reviews 3, 23-41.
58. Setem J, Pinheiro AP, Motta VA, Morato S, et al. (1999). Ethopharmacological analysis of 5-HT ligands on the rat elevated plus-maze. Pharmacology, Biochemistry, and Behavior 62, 515-521. (Pubitemid 29117195)
59. Stein DJ, Ahokas AA, de Bodinat C (2008). Efficacy of agomelatine in generalized anxiety disorder : A randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 28, 561-566.
60. Teixeira RC, Zangrossi H, Graeff FG (2000). Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacology, Biochemistry, and Behavior 65, 571-576. (Pubitemid 30182498)
61. van der Stelt HM, Breuer ME, Olivier B, Westenberg HG (2005). Permanent deficits in serotonergic functioning of olfactory bulbectomized rats : An in vivo microdialysis study. Biological Psychiatry 57, 1061-1067. (Pubitemid 40603089)
62. Vertes RP (1991). A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. Journal of Comparative Neurology 313, 643-668.
63. Walker EA, Kohut SJ, Hass RW, Brown EK, et al. (2005). Selective and nonselective serotonin antagonists block the aversive stimulus properties of MK212 and m-chlorophenylpiperazine (mCPP) in mice. Neuropharmacology 49, 1210-1219. (Pubitemid 41608645)
64. Yamauchi M, Tatebayashi T, Nagase K, Kojima M, et al. (2004). Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats. Pharmacology, Biochemistry, and Behavior 78, 683-689. (Pubitemid 39037726)
65. Zangrossi H, Graeff FG (1997). Behavioral validation of the elevated T-maze, a new animal model of anxiety. Brain Research Bulletin 44, 1-5. (Pubitemid 27375172)
66. Zangrossi H, Viana MB, Graeff FG (1999). Anxiolytic effect of intra-amygdala injection of midazolam and 8-hydroxy-2-(di-n-propylamino)tetralin in the elevated T-maze. European Journal of Pharmacology 369, 267-270. (Pubitemid 29155290)
67. Zanoveli JM, Nogueira RL, Zangrossi H (2003). Serotonin in the dorsal periaqueductal gray modulates inhibitory avoidance and one-way escape behaviors in the elevated T-maze. European Journal of Pharmacology 473, 153-161. (Pubitemid 36934488)